-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
– This round of financing will be used to accelerate the development of Ming Biologics-led clinical programs IO-108 and IO-202, while expanding its pipeline of differentiated myeloid cell checkpoint inhibitor tumor immunity products
– This round of financing will be used to accelerate the development of Ming Biologics-led clinical programs IO-108 and IO-202, while expanding its pipeline of differentiated myeloid cell checkpoint inhibitor tumor immunity products– Eming Biotech will be invited to attend industry panel discussions and introduce more about the company's and clinical progress with investors and potential partners attending the 41st J.
P.
Morgan Annual Healthcare Conference
P.
Morgan Annual Healthcare Conference–
Palo Alto, USA, Hangzhou, China, January 6, 2023 – Immune-Onc, an innovative clinical-stage biopharmaceutical company dedicated to the development of immune checkpoint drugs targeting myeloid cells
Therapeutics,
Inc.
("Yiming Bio") today announced that it has completed a $25 million Series B expansion financing, raising a total of $131 million in Series B financing
.
The expansion financing was led by existing investor Qinzhi Capital, with the participation
of new and old investors such as Proxima Venture Capital, Qianzhan Investment, and BOCOM International.
In addition, the Company continues to receive access to the Leukemia and Lymphoma Society (LLS) Treatment Acceleration Program (
TAP®) and WuXi Biologics Investment Fund's strategic capital investment
.
This round of financing will be used to accelerate the development of the company's main clinical drugs IO-108 and IO-202, and to advance other novel myeloid cell checkpoint inhibitor projects
.
At the upcoming one-on-one investor and potential partner meeting at the 41st J.
P.
Morgan Annual Healthcare Conference, Eming Biologics will provide more information
on the company's and clinical progress.
.
The expansion financing was led by existing investor Qinzhi Capital, with the participation
of new and old investors such as Proxima Venture Capital, Qianzhan Investment, and BOCOM International.
In addition, the Company continued to receive financing from the Leukemia and Lymphoma Society (LLS) Treatment Acceleration Program ( TAP®) and WuXi Biologics Investment Fund's strategic capital investment
.
Dr.
Xiaoling Liao
Xiaoling Liao
Founder, CEO and Chairman of Yiming Biotechnology
Founder, CEO and Chairman of Yiming Biotechnology"In the past year, Eming Biologics has achieved amazing growth and development, including two myeloid cell immune checkpoint inhibitor programs in China and the United States for the treatment of multiple cancers
with urgent clinical needs.
We are confident in the long-term development prospects of Eming Biologics and believe that the progress made by the company over the past year has laid a strong foundation
for continued success in 2023.
" We are well on track to several key milestones in clinical medicines, including obtaining proof-of-concept results for IO-202 dose expansion cohorts in leukemia and IO-108 in solid tumors, completing the dose escalation of IO-202 for solid tumors, and further research on clinical biomarkers and drug mechanisms of action to guide new clinical programs
.
”
2022 Highlights Review
2022 Highlights Review- Clinical aspects -
- Clinical aspects -As a target for leukocyte immunoglobulin-like receptor B2
A novel myeloid checkpoint inhibitor (LILRB2, also known as ILT4), IO-108 for the treatment of adult patients with advanced or refractory solid tumors, completed the first patient dose
.
IO-108 was approved by the Center for Drug Evaluation of the State Medical Products Administration of China for new drug clinical trials, and successfully completed the dosing
of the first patient in the phase I clinical study of advanced solid tumors in China.
IO-202, the world's first myeloid checkpoint inhibitor targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3), was dosed
in the first solid tumor patient in the US phase I clinical trial.
IO-202 for the treatment of relapsed or refractory acute myeloid leukemia (AML) received fast-track designation
from the US Food and Drug Administration.
- Corporate side -
- Corporate side -With Regeneron Pharmaceuticals,
Inc.
("Regeneron") entered into a clinical supply agreement to evaluate the combination of IO-108 and regeneron anti-PD-1 therapy Libtayo® (cimiplimab) in a U.
S.
clinical development program
.
Entered into a clinical trial collaboration and drug supply agreement with BeiGene to evaluate the therapeutic potential
of IO-108 or IO-202 in combination with BeiGene's anti-PD-1 antibody tislelizumab in a Chinese clinical development program.
Dr.
Austin L.
Gurney and Barbara J.
Klencke, M.
D.
, were appointed to the Board of Directors of the Company, Christopher
Whitmore is the company's chief financial officer
.
Won the "2022 R&D Achievement Award"
of Baihua Association.
Named to the top five life sciences companies led by women in the San Francisco Bay Area
.
Upcoming Attendance
Upcoming AttendanceOn January 10, 2023, attended Fierce JPM
Week explores the future
of immune checkpoint inhibitors and tumor immunotherapy.
For more information about the conference, please visit _istranslated="1">.
About Yiming Bio
About Yiming BioYiming Biotech is a biopharmaceutical company in the clinical research and development stage, focusing on cancer immunotherapy and is committed to developing new myeloid cell immune checkpoint inhibitors
for cancer patients.
The company's goal is to discover and develop first-of-its-kind biologic drugs
that can relieve immunosuppression in the tumor microenvironment by reversing unique scientific insights into myeloid cell biology and immunosuppressive receptors.
The company has created a number of promising product pipelines
around the immune checkpoint of myeloid cells, leukocyte immunoglobulin-like receptor subfamily B (LILRB), using the synergistic effect of the biological platform.
These include two world-first drugs in clinical development: IO-108, a new inhibitory antibody targeting LILRB2 (also known as ILT4) against solid tumors, entered the clinic in 2021; IO-202, an inhibitory antibody targeting LILRB4 (also known as ILT3), entered clinical trials in 2020 and has now been launched for phase I clinical trials
for hematological and solid tumors.
The U.
S
.
Food and Drug Administration (FDA) granted IO-202 orphan drug designation and fast-track designation for use in acute myeloid leukemia.
In addition, the Company's pipeline includes IO-106, a first-in-class inhibitory antibody targeting LAIR1 and IO-312, a first-in-class bispecific antibody targeting LILRB4, as well as multiple undisclosed programs
targeting solid tumors and hematologic malignancies.
Eming Biologics has partnered with industry-leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development initiatives
for IO-108 and IO-202 programs.
The company has also received research grants from the National Cancer Institute (NCI) and the California Institute for Regenerative Medicine (CIRM), part of the National Institutes of Health (NIH), as well as the Leukemia and Lymphoma Society (LLS) Treatment Acceleration Program (
TAP®).
Headquartered in Palo Alto, California, with operations in Hangzhou and Shanghai, China, Eming Biologics has assembled a diverse team
with extensive experience in drug development and deep experience in the world's top biotechnology companies.
For more information about the company, visit or follow the company's Twitter and LinkedIn accounts
.
Past Review
